Bladder Cancer Updates & SC Amivantamab
Update: 2025-12-18
Description
Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data.
Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.
Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
